L

Lytix Biopharma AS
F:6BG

Watchlist Manager
Lytix Biopharma AS
F:6BG
Watchlist
Price: 0.778 EUR -0.51% Market Closed
Market Cap: 473.5k EUR
Section:
 

Relative Value

6BG price has not been updated for more than 4 years. This may indicate that the stock has been delisted.

The Relative Value of one 6BG stock under the Base Case scenario is 0.006 EUR. Compared to the current market price of 0.778 EUR, Lytix Biopharma AS is Overvalued by 99%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

6BG Relative Value
Base Case
0.006 EUR
Overvaluation 99%
Relative Value
Price
L
Worst Case
Base Case
Best Case

Valuation Multiples

1 059.9
P/S
P/S
Price to Sales
1 059.9
vs History
10
vs Industry
25
Median 3Y
68.8
Median 5Y
49.5
Industry
8.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-6.2
Industry
24.2
Forward
-9.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-5.9
Industry
23
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-5.8
Industry
25.5
More Details
7.2
P/B
P/B
Price to Book Value
7.2
vs History
17
vs Industry
9
Median 3Y
4.7
Median 5Y
3.5
Industry
3.3
More Details
963.9
EV/S
EV/S
Enterprise Value to Sales
963.9
vs History
10
vs Industry
22
Median 3Y
49
Median 5Y
36.9
Industry
8.6
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-3.3
Industry
6.1
Forward
-9.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-3.3
Industry
6.6
Forward
-9.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-3.6
Median 5Y
-4.1
Industry
8.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-3.6
Median 5Y
-4.1
Industry
6.8
More Details
12.4
EV/IC
EV/IC
Enterprise Value to IC
12.4
vs History
73
vs Industry
8
Median 3Y
25.3
Median 5Y
28.3
Industry
5.7
More Details

Multiples Across Competitors

6BG Competitors Multiples
Lytix Biopharma AS Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Lytix Biopharma AS
F:6BG
644.4m EUR 1 059.9 -8.8 -8 -7.9
IL
Can Fite Biopharma Ltd
TASE:CANF
154.5T ILS 56 126 368 -3 854 397.8 -3 782 344.2 -3 773 924.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 079 720.5 -161 975.9 -196 690.4 -194 445.9
US
Abbvie Inc
NYSE:ABBV
391.8B USD 6.6 166.9 16.2 23
US
Amgen Inc
NASDAQ:AMGN
174.5B USD 4.9 24.9 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
151.2B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.5B USD 9.9 31.4 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.2 -527.5 -574.4 -559.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.9B USD 5.6 17.5 16.6 18.9
AU
CSL Ltd
ASX:CSL
84B AUD 3.6 18.7 12.6 15.7
NL
argenx SE
XBRU:ARGX
42.7B EUR 13.8 32.4 55.7 57.2
P/S Multiple
Revenue Growth P/S to Growth
NO
L
Lytix Biopharma AS
F:6BG
Average P/S: 8 200 842.3
1 059.9
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
56 126 368
140%
400 902.6
FR
Pharnext SCA
OTC:PNEXF
34 079 720.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 067.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
13.8
49%
0.3
P/E Multiple
Earnings Growth PEG
NO
L
Lytix Biopharma AS
F:6BG
Average P/E: 44.3
Negative Multiple: -8.8 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 854 397.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 975.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166.9
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
10%
1.7
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
NL
argenx SE
XBRU:ARGX
32.4
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
L
Lytix Biopharma AS
F:6BG
Average EV/EBITDA: 22.1
Negative Multiple: -8 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 782 344.2 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 690.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
NL
argenx SE
XBRU:ARGX
55.7
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
L
Lytix Biopharma AS
F:6BG
Average EV/EBIT: 24.2
Negative Multiple: -7.9 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 773 924.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 445.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
NL
argenx SE
XBRU:ARGX
57.2
N/A N/A

See Also

Summary
6BG intrinsic value, competitors valuation, and company profile.
DCF Valuation
6BG stock valuation using Discount Cash Flow valuation method.
Relative Valuation
6BG stock valuation using valuation multiples.
Wall Street Estimates
6BG price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
6BG stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.